Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Finance Watch: Deerfield Invests $635m In New York Start-Ups, Pledges $2bn Globally By 2030

Fri, 09/27/2019 - 2:43pm

Private Company Edition: Deerfield is funding a new life science campus. Also, BioFractura gets up to $67.4m in BARDA contract...

      Related Stories 

Pfizer Continues Positive Data Readouts For JAK Inhibitor Abrocitinib In Eczema

Fri, 09/27/2019 - 1:42pm

A second Phase III JADE study showed statistically significant skin clearance and reduced pruritus in atopic dermatitis, although safety is...

      Related Stories 

Pipeline Watch: Roxadustat, Lascufloxacin Approvals In Japan

Fri, 09/27/2019 - 8:37am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

Genmab Cash Pile To Grow With Another Darzalex OK

Fri, 09/27/2019 - 7:31am

The Danish biotech will be getting more revenues from its J&J-partnered multiple myeloma blockbuster following a new US approval. Analysts...

      Related Stories 

Danish Design: How Danes Aim To Grow Their Life Sciences Output

Fri, 09/27/2019 - 7:05am

Denmark has generated high growth rates from its life science industry. The country's government, industry and academic centers are increasingly...

      Related Stories 

Stempeutics Eyes Global Markets For New Crohn's Symptom Cell Therapy

Thu, 09/26/2019 - 3:53pm

Stempeutics explores stem cell therapy in India for Crohn’s disease-related perianal fistulae while considering entry into other Asian markets.

      Related Stories 

Blog: No Easy Cure For Britain’s Brexit Madness

Thu, 09/26/2019 - 8:37am

Prime Minister Boris Johnson has until 19 October to agree a deal, or otherwise must ask for another Brexit extension...

      Related Stories 

Allergy Therapeutics: We’ve Learned From Our ‘Birch Mistakes’

Thu, 09/26/2019 - 1:41am

Allergy Therapeutics says it has learned lessons from its failed Phase III birch pollen allergy trial and is applying those...

      Related Stories 

Approval Positions Roxadustat As Japan HIF-PHI Pioneer

Wed, 09/25/2019 - 7:14pm

The latest batch of product approvals in Japan positions Astellas’s roxadustat as the pioneer in the country’s potentially large HIF-PH...

      Related Stories 

Pages